Allergan extends offer on Inamed

Allergan has put back its deadline on its $3.2 billion offer to buy the breast implant maker Inamed to get anti-trust clearance.

The initial offer was to end on January 24th but it will now expire on February 5th.

The remaining hurdle is for Inamed to sell off its licence for Reloxin, the wrinkle removing botulism toxin, a product similar to Allergan’s Botox.

David Pyott, Allergan chairman, president and chief executive, said: “We are confident we will reach a successful outcome in the US antitrust review and we are progressing to close the acquisition in the near future so we can execute the integration plan.”

The merger will combine the two companies’ portfolios of medical aesthetics products and lead to cross-marketing and cross-selling opportunities.

© Adfero Ltd